Temasek's Strategic Shifts
Temasek Significantly Increases UnitedHealth and China ETF Holdings, Trims Qualcomm Stake
Anonymous
Key Points
1
RBF Capital LLC’s MCHI trim came after selling 10,000 shares, and the ETF was reported with a 12-month range of $53.40–$67.37, a beta of 0.32, and a market capitalization of about $6.34 billion (with a P/E ratio cited as 13.11).
2
Other investors also expanded exposure to China’s large-cap basket: JPMorgan Chase & Co. increased its FXI stake by 276.1% to 4,266,142 shares (valued at $175.509 million) after buying an additional 3,131,897 shares, according to the same FXI disclosure roundup.
3
For UnitedHealth (UNH), analysts cited alongside Temasek’s filing included JPMorgan raising its UNH price target from $420 to $466 and reiterating an “overweight” rating, while TD Cowen lifted its target from $311 to $337 and kept a “hold” rating.
4
Temasek’s Qualcomm (QCOM) reduction occurred alongside other changes from investors, including Rakuten Investment Management, which raised its Qualcomm stake by 162.1% to 228,765 shares valued at $39.675 million after adding 141,486 shares.
5
Temasek’s KWEB increase was described as making the China Internet ETF about 0.7% of its holdings and the 28th-largest holding, with KWEB shares opening at $26.62 and a cited 52-week low of $25.90.
Singapore's state-owned investment firm Temasek Holdings made one of its boldest single-quarter moves in recent memory, growing its stake in UnitedHealth Group by 531.4% — buying enough shares to push its position to 222,874 shares worth about $73.6 million, according to Watchlist News. The dramatic swing signals a deliberate shift away from volatile tech stocks and toward stable U.S. healthcare.
At the same time, Temasek nearly doubled its bet on Chinese internet stocks and slashed its Qualcomm position by 62.5%. The moves paint a clear picture: lock in tech gains, hedge with healthcare, and bet big on a China rebound.
Temasek's 531% UnitedHealth Bet Signals Healthcare Pivot
Temasek added roughly 187,000 UnitedHealth shares in Q4, pushing its total to 222,874 shares valued at $73.6 million, per Watchlist News. The implied share price at the time of filing was around $330. That makes this one of the largest single-quarter sovereign wealth moves into U.S. managed care in recent years.
Wall Street analysts backed the trade. JPMorgan raised its UnitedHealth price target from $420 to $466 and kept an "overweight" rating. TD Cowen was more cautious, lifting its target from $311 to $337 with a "hold" rating — suggesting the stock may be approaching fair value even as Temasek buys in.
Qualcomm Stake Cut 62.5% as AI Premium Fades
Temasek sold 78,248 Qualcomm shares in the quarter, cutting its position to just 46,971 shares worth about $8 million, according to Watchlist News. Qualcomm had surged on AI enthusiasm through late 2025. Temasek appears to be locking in those gains now.
The timing was sharp. Qualcomm shares fell 6.96% in a single day on June 10, dropping to $191.12, per Zacks Investment Research. The company still reported strong earnings — $2.65 per share on $10.6 billion in revenue — and announced a new $20 billion buyback plan. But institutional money is moving out regardless.
Big Money Floods Back Into China ETFs
Temasek nearly doubled its position in the KraneShares CSI China Internet ETF (KWEB), raising its stake by 98.5% to 6.5 million shares worth around $221.3 million. KWEB is now the fund's 28th-largest holding, making up about 0.7% of its total portfolio. KWEB shares opened at $26.62, just above a 52-week low of $25.90.
Other major players moved in the same direction. JPMorgan Chase boosted its position in the iShares China Large-Cap ETF (FXI) by 276.1%, buying 3.13 million additional shares to reach 4.27 million shares worth $175.5 million, per Ticker Report. Graham Capital Management raised its FXI stake by 65.7% to 333,000 shares worth $12.8 million. Not everyone agreed — RBF Capital trimmed its iShares MSCI China ETF (MCHI) position by 20%, selling 10,000 shares.
Temasek's Broader Strategy: Defensive Hedges, Opportunistic China Bets
Temasek manages a record portfolio worth roughly S$434 billion (about US$340 billion), per Reuters. Its Q4 moves reflect two parallel bets. First, it is rotating into U.S. healthcare as a defensive hedge against tech volatility and possible recession. Second, it is doubling down on China at what it sees as deep-value prices.
Temasek also added 512,000 shares of the iShares MSCI India ETF (INDA) worth $27.67 million and grew its NetEase stake by 28.3% to 469,728 shares, per Watchlist News. The pattern is clear: reduce concentrated tech risk in the West, add exposure to Asia's two biggest growth stories. Whether the China bet pays off depends on whether a stimulus-driven recovery materializes — or stays a promise.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
11
Reach
32
A
AnonymousAuthor
